UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups

Circulation (New York, N.Y.), 2019-03, Vol.139 (12), p.1472-1482

2019

Volltextzugriff (PDF)

Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor

The Journal of biological chemistry, 2015-05, Vol.290 (18), p.11649-11662

2015

Volltextzugriff (PDF)

Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis

Atherosclerosis, 2022-05, Vol.349, p.72-81

Boffa, Michael B.

2022

Volltextzugriff (PDF)

Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion

Arteriosclerosis, thrombosis, and vascular biology, 2022-03, Vol.42 (3), p.289-304

2022

Volltextzugriff (PDF)

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)

Journal of lipid research, 2013-10, Vol.54 (10), p.2815-2830

2013

Volltextzugriff (PDF)

Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis

Journal of lipid research, 2019-12, Vol.60 (12), p.2082-2089

2019

Volltextzugriff (PDF)

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)

Journal of lipid research, 2015-12, Vol.56 (12), p.2273-2285

2015

Volltextzugriff (PDF)

Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease

Current atherosclerosis reports, 2016-12, Vol.18 (12), p.69-69, Article 69

Boffa, Michael B.

2016

Volltextzugriff (PDF)

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9

PloS one, 2017-07, Vol.12 (7), p.e0180869-e0180869

2017

Volltextzugriff (PDF)

Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis

Journal of thrombosis and haemostasis, 2023-04, Vol.21 (4), p.1043-1054

2023

Volltextzugriff (PDF)

Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a)

Journal of lipid research, 2022-06, Vol.63 (6), p.100216-100216, Article 100216

2022

Volltextzugriff (PDF)

Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13

Scientific reports, 2024-04, Vol.14 (1), p.9073-9073, Article 9073

2024

Volltextzugriff (PDF)

Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential

Research and practice in thrombosis and haemostasis, 2024-05, Vol.8 (4), p.102459, Article 102459

2024

Volltextzugriff (PDF)

Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease

Nature reviews cardiology, 2019-05, Vol.16 (5), p.305-318

2019

Volltextzugriff (PDF)

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)[S]

Journal of lipid research, 2014-04, Vol.55 (4), p.625-634

2014

Volltextzugriff (PDF)

Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology

Atherosclerosis, 2022-05, Vol.349, p.92-100

2022

Volltextzugriff (PDF)

Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system

PloS one, 2013, Vol.8 (1), p.e52287-e52287

2013

Volltextzugriff (PDF)

Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Journal of lipid research, 2016-05, Vol.57 (5), p.745-757

2016

Volltextzugriff (PDF)

LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study

Molecular therapy. Methods & clinical development, 2022-12, Vol.27, p.337-351

2022

Volltextzugriff (PDF)

Lipoprotein(a) and cardiovascular disease

Biochemical journal, 2024-10, Vol.481 (19), p.1277-1296

2024

Volltextzugriff (PDF)

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis

BMC cancer, 2016-05, Vol.16 (330), p.328-328, Article 328

2016

Volltextzugriff (PDF)

Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles

Clinical biochemistry, 2007-04, Vol.40 (7), p.431-442

2007

Volltextzugriff (PDF)

Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages

Frontiers in cardiovascular medicine, 2023-05, Vol.10, p.1130162-1130162

2023

Volltextzugriff (PDF)

Genetics to the Rescue: Sophisticated Approaches Provide Critical Insights Into the Determination of Lp(a) Levels

Journal of the American College of Cardiology, 2021-08, Vol.78 (5), p.450-452

2021

Volltextzugriff (PDF)

1 – 25 von 143

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(135)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Englisch
(143)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups

Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor

Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis

Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)

Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)

Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9

Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis

Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a)

Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13

Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential

Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)[S]

Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology

Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system

Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study

Lipoprotein(a) and cardiovascular disease

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis

Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles

Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages

Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis

Genetics to the Rescue: Sophisticated Approaches Provide Critical Insights Into the Determination of Lp(a) Levels

Suchergebnisse filtern